{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T11:45:05Z","timestamp":1775043905399,"version":"3.50.1"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Mammary Gland Biol Neoplasia"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1007\/s10911-011-9200-x","type":"journal-article","created":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T07:04:39Z","timestamp":1298963079000},"page":"17-25","source":"Crossref","is-referenced-by-count":32,"title":["Clinical Management of Hereditary Breast Cancer Syndromes"],"prefix":"10.1007","volume":"16","author":[{"given":"Amy S.","family":"Clark","sequence":"first","affiliation":[]},{"given":"Susan M.","family":"Domchek","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2011,3,1]]},"reference":[{"key":"9200_CR1","doi-asserted-by":"crossref","unstructured":"Jemal A et al. Cancer Statistics, 2010. CA Cancer J Clin 2010.","DOI":"10.3322\/caac.20073"},{"issue":"2","key":"9200_CR2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ccr.2007.01.010","volume":"11","author":"T Walsh","year":"2007","unstructured":"Walsh T, King MC. Ten genes for inherited breast cancer. Cancer Cell. 2007;11(2):103\u20135.","journal-title":"Cancer Cell"},{"issue":"5182","key":"9200_CR3","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1126\/science.7545954","volume":"266","author":"Y Miki","year":"1994","unstructured":"Miki Y et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266(5182):66\u201371.","journal-title":"Science"},{"issue":"6559","key":"9200_CR4","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/378789a0","volume":"378","author":"R Wooster","year":"1995","unstructured":"Wooster R et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378(6559):789\u201392.","journal-title":"Nature"},{"issue":"3","key":"9200_CR5","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1086\/301749","volume":"62","author":"D Ford","year":"1998","unstructured":"Ford D et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998;62(3):676\u201389.","journal-title":"Am J Hum Genet"},{"issue":"16","key":"9200_CR6","doi-asserted-by":"crossref","first-page":"8297","DOI":"10.1158\/0008-5472.CAN-06-0503","volume":"66","author":"KE Malone","year":"2006","unstructured":"Malone KE et al. Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64\u00a0years. Cancer Res. 2006;66(16):8297\u2013308.","journal-title":"Cancer Res"},{"issue":"43","key":"9200_CR7","doi-asserted-by":"crossref","first-page":"5864","DOI":"10.1038\/sj.onc.1209874","volume":"25","author":"K Gudmundsdottir","year":"2006","unstructured":"Gudmundsdottir K, Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene. 2006;25(43):5864\u201374.","journal-title":"Oncogene"},{"issue":"2","key":"9200_CR8","first-page":"232","volume":"48","author":"EB Claus","year":"1991","unstructured":"Claus EB, Risch N, Thompson WD. Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet. 1991;48(2):232\u201342.","journal-title":"Am J Hum Genet"},{"issue":"6","key":"9200_CR9","first-page":"1457","volume":"57","author":"D Ford","year":"1995","unstructured":"Ford D, Easton DF, Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet. 1995;57(6):1457\u201362.","journal-title":"Am J Hum Genet"},{"issue":"3","key":"9200_CR10","first-page":"496","volume":"60","author":"AS Whittemore","year":"1997","unstructured":"Whittemore AS, Gong G, Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet. 1997;60(3):496\u2013504.","journal-title":"Am J Hum Genet"},{"issue":"23","key":"9200_CR11","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/jnci\/djj465","volume":"98","author":"HA Risch","year":"2006","unstructured":"Risch HA et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst. 2006;98(23):1694\u2013706.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"9200_CR12","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1200\/JCO.2009.25.0712","volume":"28","author":"KA Metcalfe","year":"2010","unstructured":"Metcalfe KA et al. Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women. J Clin Oncol. 2010;28(3):387\u201391.","journal-title":"J Clin Oncol"},{"issue":"2","key":"9200_CR13","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jama.2007.55-a","volume":"299","author":"CB Begg","year":"2008","unstructured":"Begg CB et al. Variation of breast cancer risk among BRCA1\/2 carriers. JAMA. 2008;299(2):194\u2013201.","journal-title":"JAMA"},{"issue":"11","key":"9200_CR14","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","volume":"25","author":"S Chen","year":"2007","unstructured":"Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25(11):1329\u201333.","journal-title":"J Clin Oncol"},{"issue":"5","key":"9200_CR15","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","volume":"72","author":"A Antoniou","year":"2003","unstructured":"Antoniou A et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117\u201330.","journal-title":"Am J Hum Genet"},{"issue":"4","key":"9200_CR16","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/ng1295-428","volume":"11","author":"SA Gayther","year":"1995","unstructured":"Gayther SA et al. Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet. 1995;11(4):428\u201333.","journal-title":"Nat Genet"},{"issue":"1","key":"9200_CR17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/ng0197-103","volume":"15","author":"SA Gayther","year":"1997","unstructured":"Gayther SA et al. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet. 1997;15(1):103\u20135.","journal-title":"Nat Genet"},{"issue":"23","key":"9200_CR18","doi-asserted-by":"crossref","first-page":"9742","DOI":"10.1158\/0008-5472.CAN-10-1907","volume":"70","author":"AC Antoniou","year":"2010","unstructured":"Antoniou AC et al. Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res. 2010;70(23):9742\u201354.","journal-title":"Cancer Res"},{"issue":"2","key":"9200_CR19","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/(SICI)1098-2272(200002)18:2<173::AID-GEPI6>3.0.CO;2-R","volume":"18","author":"AC Antoniou","year":"2000","unstructured":"Antoniou AC et al. Risk models for familial ovarian and breast cancer. Genet Epidemiol. 2000;18(2):173\u201390.","journal-title":"Genet Epidemiol"},{"issue":"18","key":"9200_CR20","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1093\/jnci\/94.18.1365","volume":"94","author":"MS Brose","year":"2002","unstructured":"Brose MS et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst. 2002;94(18):1365\u201372.","journal-title":"J Natl Cancer Inst"},{"key":"9200_CR21","unstructured":"Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst 1999;91(15):1310\u20136."},{"issue":"7","key":"9200_CR22","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1136\/jmg.2006.048173","volume":"44","author":"L Kadouri","year":"2007","unstructured":"Kadouri L et al. Cancer risks in carriers of the BRCA1\/2 Ashkenazi founder mutations. J Med Genet. 2007;44(7):467\u201371.","journal-title":"J Med Genet"},{"issue":"18","key":"9200_CR23","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1093\/jnci\/94.18.1358","volume":"94","author":"D Thompson","year":"2002","unstructured":"Thompson D, Easton DF. Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst. 2002;94(18):1358\u201365.","journal-title":"J Natl Cancer Inst"},{"issue":"23","key":"9200_CR24","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/jnci\/djm203","volume":"99","author":"YC Tai","year":"2007","unstructured":"Tai YC et al. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2007;99(23):1811\u20134.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"9200_CR25","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/ng1096-185","volume":"14","author":"BB Roa","year":"1996","unstructured":"Roa BB et al. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet. 1996;14(2):185\u20137.","journal-title":"Nat Genet"},{"issue":"1","key":"9200_CR26","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1089\/gte.1997.1.47","volume":"1","author":"M Robson","year":"1997","unstructured":"Robson M et al. Prevalence of recurring BRCA mutations among Ashkenazi Jewish women with breast cancer. Genet Test. 1997;1(1):47\u201351.","journal-title":"Genet Test"},{"issue":"17","key":"9200_CR27","doi-asserted-by":"crossref","first-page":"7006","DOI":"10.1158\/0008-5472.CAN-08-0599","volume":"68","author":"MD Palma","year":"2008","unstructured":"Palma MD et al. The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families. Cancer Res. 2008;68(17):7006\u201314.","journal-title":"Cancer Res"},{"issue":"12","key":"9200_CR28","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1001\/jama.295.12.1379","volume":"295","author":"T Walsh","year":"2006","unstructured":"Walsh T et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA. 2006;295(12):1379\u201388.","journal-title":"JAMA"},{"issue":"9473","key":"9200_CR29","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/S0140-6736(05)66481-1","volume":"365","author":"MO Leach","year":"2005","unstructured":"Leach MO et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet. 2005;365(9473):1769\u201378.","journal-title":"Lancet"},{"issue":"5","key":"9200_CR30","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa031759","volume":"351","author":"M Kriege","year":"2004","unstructured":"Kriege M et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med. 2004;351(5):427\u201337.","journal-title":"N Engl J Med"},{"issue":"9","key":"9200_CR31","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1200\/JCO.2009.23.0839","volume":"28","author":"C Kuhl","year":"2010","unstructured":"Kuhl C et al. Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. J Clin Oncol. 2010;28(9):1450\u20137.","journal-title":"J Clin Oncol"},{"issue":"36","key":"9200_CR32","doi-asserted-by":"crossref","first-page":"5265","DOI":"10.1200\/JCO.2009.27.2294","volume":"28","author":"AJ Rijnsburger","year":"2010","unstructured":"Rijnsburger AJ et al. BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study. J Clin Oncol. 2010;28(36):5265\u201373.","journal-title":"J Clin Oncol"},{"issue":"4","key":"9200_CR33","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/ijc.24038","volume":"124","author":"NM Velde van der","year":"2009","unstructured":"van der Velde NM et al. Time to stop ovarian cancer screening in BRCA1\/2 mutation carriers? Int J Cancer. 2009;124(4):919\u201323.","journal-title":"Int J Cancer"},{"issue":"23","key":"9200_CR34","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","volume":"295","author":"VG Vogel","year":"2006","unstructured":"Vogel VG et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295(23):2727\u201341.","journal-title":"JAMA"},{"issue":"22","key":"9200_CR35","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1093\/jnci\/dji372","volume":"97","author":"B Fisher","year":"2005","unstructured":"Fisher B et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97(22):1652\u201362.","journal-title":"J Natl Cancer Inst"},{"issue":"18","key":"9200_CR36","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.286.18.2251","volume":"286","author":"MC King","year":"2001","unstructured":"King MC et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA. 2001;286(18):2251\u20136.","journal-title":"JAMA"},{"issue":"9","key":"9200_CR37","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1002\/ijc.21536","volume":"118","author":"J Gronwald","year":"2006","unstructured":"Gronwald J et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer. 2006;118(9):2281\u20134.","journal-title":"Int J Cancer"},{"issue":"23","key":"9200_CR38","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1093\/jnci\/94.23.1773","volume":"94","author":"SA Narod","year":"2002","unstructured":"Narod SA et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2002;94(23):1773\u20139.","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"9200_CR39","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1038\/sj.bjc.6602239","volume":"91","author":"AS Whittemore","year":"2004","unstructured":"Whittemore AS et al. Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. Br J Cancer. 2004;91(11):1911\u20135.","journal-title":"Br J Cancer"},{"issue":"25","key":"9200_CR40","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1200\/JCO.2007.11.1179","volume":"25","author":"RM Brohet","year":"2007","unstructured":"Brohet RM et al. Oral contraceptives and breast cancer risk in the international BRCA1\/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. J Clin Oncol. 2007;25(25):3831\u20136.","journal-title":"J Clin Oncol"},{"issue":"10","key":"9200_CR41","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1158\/1055-9965.EPI-06-0258","volume":"15","author":"RW Haile","year":"2006","unstructured":"Haile RW et al. BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. Cancer Epidemiol Biomark Prev. 2006;15(10):1863\u201370.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"21","key":"9200_CR42","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1093\/jnci\/93.21.1633","volume":"93","author":"LC Hartmann","year":"2001","unstructured":"Hartmann LC et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 2001;93(21):1633\u20137.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"9200_CR43","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1056\/NEJM200107193450301","volume":"345","author":"H Meijers-Heijboer","year":"2001","unstructured":"Meijers-Heijboer H et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001;345(3):159\u201364.","journal-title":"N Engl J Med"},{"issue":"3","key":"9200_CR44","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/SLA.0b013e3181c3c36d","volume":"251","author":"R Kaas","year":"2010","unstructured":"Kaas R et al. Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer. Ann Surg. 2010;251(3):488\u201392.","journal-title":"Ann Surg"},{"issue":"9","key":"9200_CR45","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.2010.1237","volume":"304","author":"SM Domchek","year":"2010","unstructured":"Domchek SM et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304(9):967\u201375.","journal-title":"JAMA"},{"issue":"34","key":"9200_CR46","doi-asserted-by":"crossref","first-page":"8629","DOI":"10.1200\/JCO.2005.02.9199","volume":"23","author":"JL Kramer","year":"2005","unstructured":"Kramer JL et al. Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers. J Clin Oncol. 2005;23(34):8629\u201335.","journal-title":"J Clin Oncol"},{"issue":"8","key":"9200_CR47","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1200\/JCO.2007.13.9626","volume":"26","author":"ND Kauff","year":"2008","unstructured":"Kauff ND et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. 2008;26(8):1331\u20137.","journal-title":"J Clin Oncol"},{"issue":"2","key":"9200_CR48","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jnci\/djn442","volume":"101","author":"TR Rebbeck","year":"2009","unstructured":"Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009;101(2):80\u20137.","journal-title":"J Natl Cancer Inst"},{"issue":"30","key":"9200_CR49","doi-asserted-by":"crossref","first-page":"7491","DOI":"10.1200\/JCO.2004.00.7138","volume":"23","author":"A Eisen","year":"2005","unstructured":"Eisen A et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol. 2005;23(30):7491\u20136.","journal-title":"J Clin Oncol"},{"issue":"2","key":"9200_CR50","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/jama.296.2.185","volume":"296","author":"A Finch","year":"2006","unstructured":"Finch A et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA. 2006;296(2):185\u201392.","journal-title":"JAMA"},{"issue":"21","key":"9200_CR51","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa020119","volume":"346","author":"ND Kauff","year":"2002","unstructured":"Kauff ND et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002;346(21):1609\u201315.","journal-title":"N Engl J Med"},{"issue":"14","key":"9200_CR52","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/jnci\/95.14.1072","volume":"95","author":"JL Rutter","year":"2003","unstructured":"Rutter JL et al. Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study. J Natl Cancer Inst. 2003;95(14):1072\u20138.","journal-title":"J Natl Cancer Inst"},{"issue":"21","key":"9200_CR53","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1056\/NEJMoa012158","volume":"346","author":"TR Rebbeck","year":"2002","unstructured":"Rebbeck TR et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002;346(21):1616\u201322.","journal-title":"N Engl J Med"},{"issue":"3","key":"9200_CR54","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(06)70585-X","volume":"7","author":"SM Domchek","year":"2006","unstructured":"Domchek SM et al. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol. 2006;7(3):223\u20139.","journal-title":"Lancet Oncol"},{"issue":"2","key":"9200_CR55","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1200\/JCO.2009.22.7991","volume":"28","author":"AW Kurian","year":"2010","unstructured":"Kurian AW, Sigal BM, Plevritis SK. Survival analysis of cancer risk reduction strategies for BRCA1\/2 mutation carriers. J Clin Oncol. 2010;28(2):222\u201331.","journal-title":"J Clin Oncol"},{"issue":"5","key":"9200_CR56","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1097\/AOG.0b013e3181a11c64","volume":"113","author":"WH Parker","year":"2009","unstructured":"Parker WH et al. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses\u2019 health study. Obstet Gynecol. 2009;113(5):1027\u201337.","journal-title":"Obstet Gynecol"},{"issue":"10","key":"9200_CR57","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S1470-2045(06)70869-5","volume":"7","author":"WA Rocca","year":"2006","unstructured":"Rocca WA et al. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol. 2006;7(10):821\u20138.","journal-title":"Lancet Oncol"},{"issue":"22","key":"9200_CR58","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.2005.05.1896","volume":"24","author":"JB Madalinska","year":"2006","unstructured":"Madalinska JB et al. The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. J Clin Oncol. 2006;24(22):3576\u201382.","journal-title":"J Clin Oncol"},{"issue":"31","key":"9200_CR59","doi-asserted-by":"crossref","first-page":"7804","DOI":"10.1200\/JCO.2004.00.8151","volume":"23","author":"TR Rebbeck","year":"2005","unstructured":"Rebbeck TR et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2005;23(31):7804\u201310.","journal-title":"J Clin Oncol"},{"issue":"19","key":"9200_CR60","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/jnci\/djn313","volume":"100","author":"A Eisen","year":"2008","unstructured":"Eisen A et al. Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst. 2008;100(19):1361\u20137.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"9200_CR61","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa070608","volume":"357","author":"G Rennert","year":"2007","unstructured":"Rennert G et al. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med. 2007;357(2):115\u201323.","journal-title":"N Engl J Med"},{"issue":"1","key":"9200_CR62","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10549-009-0566-z","volume":"119","author":"L Bordeleau","year":"2010","unstructured":"Bordeleau L, Panchal S, Goodwin P. Prognosis of BRCA-associated breast cancer: a summary of evidence. Breast Cancer Res Treat. 2010;119(1):13\u201324.","journal-title":"Breast Cancer Res Treat"},{"issue":"9737","key":"9200_CR63","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(10)60892-6","volume":"376","author":"A Tutt","year":"2010","unstructured":"Tutt A et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376(9737):235\u201344.","journal-title":"Lancet"},{"issue":"3","key":"9200_CR64","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1200\/JCO.2008.20.7019","volume":"28","author":"T Byrski","year":"2010","unstructured":"Byrski T et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol. 2010;28(3):375\u20139.","journal-title":"J Clin Oncol"},{"issue":"7","key":"9200_CR65","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1200\/JCO.2009.22.4725","volume":"28","author":"DP Silver","year":"2010","unstructured":"Silver DP et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol. 2010;28(7):1145\u201353.","journal-title":"J Clin Oncol"},{"issue":"8","key":"9200_CR66","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/bies.20085","volume":"26","author":"JC Ame","year":"2004","unstructured":"Ame JC, Spenlehauer C, de Murcia G. The PARP superfamily. Bioessays. 2004;26(8):882\u201393.","journal-title":"Bioessays"},{"issue":"25","key":"9200_CR67","doi-asserted-by":"crossref","first-page":"7559","DOI":"10.1021\/bi0003442","volume":"39","author":"F Dantzer","year":"2000","unstructured":"Dantzer F et al. Base excision repair is impaired in mammalian cells lacking Poly(ADP-ribose) polymerase-1. Biochemistry. 2000;39(25):7559\u201369.","journal-title":"Biochemistry"},{"issue":"16","key":"9200_CR68","doi-asserted-by":"crossref","first-page":"8109","DOI":"10.1158\/0008-5472.CAN-06-0140","volume":"66","author":"N McCabe","year":"2006","unstructured":"McCabe N et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006;66(16):8109\u201315.","journal-title":"Cancer Res"},{"issue":"22","key":"9200_CR69","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1200\/JCO.2008.16.0812","volume":"26","author":"A Ashworth","year":"2008","unstructured":"Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol. 2008;26(22):3785\u201390.","journal-title":"J Clin Oncol"},{"issue":"7035","key":"9200_CR70","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer H et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917\u201321.","journal-title":"Nature"},{"issue":"7035","key":"9200_CR71","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant HE et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913\u20137.","journal-title":"Nature"},{"issue":"2","key":"9200_CR72","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","volume":"361","author":"PC Fong","year":"2009","unstructured":"Fong PC et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123\u201334.","journal-title":"N Engl J Med"},{"issue":"9737","key":"9200_CR73","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(10)60893-8","volume":"376","author":"MW Audeh","year":"2010","unstructured":"Audeh MW et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010;376(9737):245\u201351.","journal-title":"Lancet"},{"issue":"2","key":"9200_CR74","first-page":"344","volume":"51","author":"ED Lustbader","year":"1992","unstructured":"Lustbader ED et al. Segregation analysis of cancer in families of childhood soft-tissue-sarcoma patients. Am J Hum Genet. 1992;51(2):344\u201356.","journal-title":"Am J Hum Genet"},{"key":"9200_CR75","unstructured":"Garber KSaJ. Li-Fraumeni Syndrome in SBLA (Sarcoma, Breast, Leukemia and Adrenal Gland), B.T. Pagon RA, Dolan CR et al., Editor. GeneReviews: Seattle 2010."},{"issue":"3","key":"9200_CR76","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/humu.10185","volume":"21","author":"JM Varley","year":"2003","unstructured":"Varley JM. Germline TP53 mutations and Li-Fraumeni syndrome. Hum Mutat. 2003;21(3):313\u201320.","journal-title":"Hum Mutat"},{"issue":"5","key":"9200_CR77","first-page":"1298","volume":"54","author":"JM Birch","year":"1994","unstructured":"Birch JM et al. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res. 1994;54(5):1298\u2013304.","journal-title":"Cancer Res"},{"issue":"8","key":"9200_CR78","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1200\/JCO.2008.16.6959","volume":"27","author":"KD Gonzalez","year":"2009","unstructured":"Gonzalez KD et al. Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol. 2009;27(8):1250\u20136.","journal-title":"J Clin Oncol"},{"issue":"6","key":"9200_CR79","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/sj.onc.1206155","volume":"22","author":"G Bougeard","year":"2003","unstructured":"Bougeard G et al. Screening for TP53 rearrangements in families with the Li-Fraumeni syndrome reveals a complete deletion of the TP53 gene. Oncogene. 2003;22(6):840\u20136.","journal-title":"Oncogene"},{"issue":"9","key":"9200_CR80","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/S1470-2045(09)70089-0","volume":"10","author":"MI Achatz","year":"2009","unstructured":"Achatz MI, Hainaut P, Ashton-Prolla P. Highly prevalent TP53 mutation predisposing to many cancers in the Brazilian population: a case for newborn screening? Lancet Oncol. 2009;10(9):920\u20135.","journal-title":"Lancet Oncol"},{"issue":"10","key":"9200_CR81","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/jmg.2008.058958","volume":"46","author":"KD Gonzalez","year":"2009","unstructured":"Gonzalez KD et al. High frequency of de novo mutations in Li-Fraumeni syndrome. J Med Genet. 2009;46(10):689\u201393.","journal-title":"J Med Genet"},{"issue":"4","key":"9200_CR82","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1086\/374567","volume":"72","author":"SJ Hwang","year":"2003","unstructured":"Hwang SJ et al. Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. Am J Hum Genet. 2003;72(4):975\u201383.","journal-title":"Am J Hum Genet"},{"issue":"38","key":"9200_CR83","doi-asserted-by":"crossref","first-page":"6445","DOI":"10.1038\/sj.onc.1207714","volume":"23","author":"R Nagy","year":"2004","unstructured":"Nagy R, Sweet K, Eng C. Highly penetrant hereditary cancer syndromes. Oncogene. 2004;23(38):6445\u201370.","journal-title":"Oncogene"},{"issue":"1","key":"9200_CR84","first-page":"1","volume":"150","author":"P Kleihues","year":"1997","unstructured":"Kleihues P et al. Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol. 1997;150(1):1\u201313.","journal-title":"Am J Pathol"},{"issue":"20","key":"9200_CR85","first-page":"6643","volume":"63","author":"M Olivier","year":"2003","unstructured":"Olivier M et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res. 2003;63(20):6643\u201350.","journal-title":"Cancer Res"},{"issue":"11","key":"9200_CR86","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/j.ejca.2005.01.026","volume":"41","author":"V Krutilkova","year":"2005","unstructured":"Krutilkova V et al. Identification of five new families strengthens the link between childhood choroid plexus carcinoma and germline TP53 mutations. Eur J Cancer. 2005;41(11):1597\u2013603.","journal-title":"Eur J Cancer"},{"issue":"12","key":"9200_CR87","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1054\/bjoc.2000.1167","volume":"82","author":"A Chompret","year":"2000","unstructured":"Chompret A et al. P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer. 2000;82(12):1932\u20137.","journal-title":"Br J Cancer"},{"issue":"2","key":"9200_CR88","first-page":"83","volume":"10","author":"KE Nichols","year":"2001","unstructured":"Nichols KE et al. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomark Prev. 2001;10(2):83\u20137.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"1","key":"9200_CR89","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1053\/j.gastro.2005.10.014","volume":"130","author":"P Wong","year":"2006","unstructured":"Wong P et al. Prevalence of early onset colorectal cancer in 397 patients with classic Li-Fraumeni syndrome. Gastroenterology. 2006;130(1):73\u20139.","journal-title":"Gastroenterology"},{"issue":"11","key":"9200_CR90","first-page":"3234","volume":"52","author":"AL Borresen","year":"1992","unstructured":"Borresen AL et al. Screening for germ line TP53 mutations in breast cancer patients. Cancer Res. 1992;52(11):3234\u20136.","journal-title":"Cancer Res"},{"issue":"10","key":"9200_CR91","first-page":"2984","volume":"52","author":"D Sidransky","year":"1992","unstructured":"Sidransky D et al. Inherited p53 gene mutations in breast cancer. Cancer Res. 1992;52(10):2984\u20136.","journal-title":"Cancer Res"},{"issue":"9363","key":"9200_CR92","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/S0140-6736(03)12856-5","volume":"361","author":"F Lalloo","year":"2003","unstructured":"Lalloo F et al. Prediction of pathogenic mutations in patients with early-onset breast cancer by family history. Lancet. 2003;361(9363):1101\u20132.","journal-title":"Lancet"},{"issue":"11","key":"9200_CR93","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1001\/jama.299.11.1315","volume":"299","author":"S Masciari","year":"2008","unstructured":"Masciari S et al. F18-fluorodeoxyglucose-positron emission tomography\/computed tomography screening in Li-Fraumeni syndrome. JAMA. 2008;299(11):1315\u20139.","journal-title":"JAMA"},{"issue":"7","key":"9200_CR94","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.clon.2007.05.001","volume":"19","author":"A Salmon","year":"2007","unstructured":"Salmon A et al. Rapid development of post-radiotherapy sarcoma and breast cancer in a patient with a novel germline \u2018de-novo\u2019 TP53 mutation. Clin Oncol R Coll Radiol. 2007;19(7):490\u20133.","journal-title":"Clin Oncol R Coll Radiol"},{"issue":"11","key":"9200_CR95","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1136\/jmg.37.11.828","volume":"37","author":"C Eng","year":"2000","unstructured":"Eng C. Will the real Cowden syndrome please stand up: revised diagnostic criteria. J Med Genet. 2000;37(11):828\u201330.","journal-title":"J Med Genet"},{"issue":"5","key":"9200_CR96","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.tripleo.2005.06.026","volume":"101","author":"MA Scheper","year":"2006","unstructured":"Scheper MA et al. Cowden syndrome: report of a case with immunohistochemical analysis and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;101(5):625\u201331.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"issue":"1","key":"9200_CR97","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/ng0597-64","volume":"16","author":"D Liaw","year":"1997","unstructured":"Liaw D et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet. 1997;16(1):64\u20137.","journal-title":"Nat Genet"},{"issue":"1","key":"9200_CR98","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.cancergencyto.2008.03.013","volume":"184","author":"G Tate","year":"2008","unstructured":"Tate G et al. A novel mutation of the PTEN gene in a Japanese patient with Cowden syndrome and bilateral breast cancer. Cancer Genet Cytogenet. 2008;184(1):67\u201371.","journal-title":"Cancer Genet Cytogenet"},{"issue":"5","key":"9200_CR99","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1046\/j.1365-2133.2003.05322.x","volume":"148","author":"J Reifenberger","year":"2003","unstructured":"Reifenberger J et al. Cowden\u2019s disease: clinical and molecular genetic findings in a patient with a novel PTEN germline mutation. Br J Dermatol. 2003;148(5):1040\u20136.","journal-title":"Br J Dermatol"},{"issue":"2","key":"9200_CR100","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1086\/377109","volume":"73","author":"XP Zhou","year":"2003","unstructured":"Zhou XP et al. Germline PTEN promoter mutations and deletions in Cowden\/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase\/Akt pathway. Am J Hum Genet. 2003;73(2):404\u201311.","journal-title":"Am J Hum Genet"},{"issue":"5","key":"9200_CR101","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1136\/jmg.37.5.336","volume":"37","author":"I Vivo De","year":"2000","unstructured":"De Vivo I et al. Novel germline mutations in the PTEN tumour suppressor gene found in women with multiple cancers. J Med Genet. 2000;37(5):336\u201341.","journal-title":"J Med Genet"},{"issue":"4","key":"9200_CR102","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1086\/521051","volume":"81","author":"RE Teresi","year":"2007","unstructured":"Teresi RE et al. Cowden syndrome-affected patients with PTEN promoter mutations demonstrate abnormal protein translation. Am J Hum Genet. 2007;81(4):756\u201367.","journal-title":"Am J Hum Genet"},{"issue":"3","key":"9200_CR103","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/hmg\/7.3.507","volume":"7","author":"DJ Marsh","year":"1998","unstructured":"Marsh DJ et al. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet. 1998;7(3):507\u201315.","journal-title":"Hum Mol Genet"},{"issue":"3","key":"9200_CR104","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/sj.ejhg.5200289","volume":"7","author":"MR Nelen","year":"1999","unstructured":"Nelen MR et al. Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype correlations. Eur J Hum Genet. 1999;7(3):267\u201373.","journal-title":"Eur J Hum Genet"},{"issue":"8","key":"9200_CR105","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ctrv.2010.04.002","volume":"36","author":"A Farooq","year":"2010","unstructured":"Farooq A et al. Cowden syndrome. Cancer Treat Rev. 2010;36(8):577\u201383.","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"9200_CR106","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ajhg.2008.07.011","volume":"83","author":"Y Ni","year":"2008","unstructured":"Ni Y et al. Germline mutations and variants in the succinate dehydrogenase genes in Cowden and Cowden-like syndromes. Am J Hum Genet. 2008;83(2):261\u20138.","journal-title":"Am J Hum Genet"},{"issue":"6","key":"9200_CR107","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1086\/301639","volume":"61","author":"ED Lynch","year":"1997","unstructured":"Lynch ED et al. Inherited mutations in PTEN that are associated with breast cancer, cowden disease, and juvenile polyposis. Am J Hum Genet. 1997;61(6):1254\u201360.","journal-title":"Am J Hum Genet"},{"issue":"6","key":"9200_CR108","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1002\/1097-0142(197806)41:6<2393::AID-CNCR2820410644>3.0.CO;2-K","volume":"41","author":"MH Brownstein","year":"1978","unstructured":"Brownstein MH, Wolf M, Bikowski JB. Cowden\u2019s disease: a cutaneous marker of breast cancer. Cancer. 1978;41(6):2393\u20138.","journal-title":"Cancer"},{"key":"9200_CR109","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3233\/BD-2007-27103","volume":"27","author":"R Nusbaum","year":"2006","unstructured":"Nusbaum R, Vogel KJ, Ready K. Susceptibility to breast cancer: hereditary syndromes and low penetrance genes. Breast Dis. 2006;27:21\u201350.","journal-title":"Breast Dis"},{"issue":"5","key":"9200_CR110","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1086\/301607","volume":"61","author":"HC Tsou","year":"1997","unstructured":"Tsou HC et al. The role of MMAC1 mutations in early-onset breast cancer: causative in association with Cowden syndrome and excluded in BRCA1-negative cases. Am J Hum Genet. 1997;61(5):1036\u201343.","journal-title":"Am J Hum Genet"},{"issue":"3","key":"9200_CR111","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1399-0004.1986.tb00816.x","volume":"29","author":"TM Starink","year":"1986","unstructured":"Starink TM et al. The Cowden syndrome: a clinical and genetic study in 21 patients. Clin Genet. 1986;29(3):222\u201333.","journal-title":"Clin Genet"},{"issue":"10","key":"9200_CR112","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/GIM.0b013e3181ac9aea","volume":"11","author":"JA Hobert","year":"2009","unstructured":"Hobert JA, Eng C. PTEN hamartoma tumor syndrome: an overview. Genet Med. 2009;11(10):687\u201394.","journal-title":"Genet Med"},{"issue":"10","key":"9200_CR113","doi-asserted-by":"crossref","first-page":"703","DOI":"10.7326\/0000605-200911170-00147","volume":"151","author":"HD Nelson","year":"2009","unstructured":"Nelson HD et al. Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer. Ann Intern Med. 2009;151(10):703\u201315. W-226-35.","journal-title":"Ann Intern Med"}],"container-title":["Journal of Mammary Gland Biology and Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10911-011-9200-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10911-011-9200-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10911-011-9200-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T18:18:08Z","timestamp":1560017888000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10911-011-9200-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,1]]},"references-count":113,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["9200"],"URL":"https:\/\/doi.org\/10.1007\/s10911-011-9200-x","relation":{},"ISSN":["1083-3021","1573-7039"],"issn-type":[{"value":"1083-3021","type":"print"},{"value":"1573-7039","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,1]]}}}